AAPL   327.75 (+1.68%)
MSFT   184.81 (+1.03%)
FB   230.09 (+1.68%)
GOOGL   1,433.00 (+1.32%)
AMZN   2,460.86 (+0.01%)
NVDA   352.84 (+0.62%)
CGC   16.91 (+1.68%)
BABA   219.25 (+0.55%)
MU   53.58 (+4.61%)
GE   8.32 (+7.36%)
TSLA   870.87 (+0.75%)
AMD   52.41 (-0.42%)
T   32.67 (+2.74%)
F   7.23 (+10.05%)
GILD   77.00 (-0.70%)
DIS   126.33 (+2.13%)
BAC   28.43 (+6.16%)
BA   207.14 (+12.39%)
AAPL   327.75 (+1.68%)
MSFT   184.81 (+1.03%)
FB   230.09 (+1.68%)
GOOGL   1,433.00 (+1.32%)
AMZN   2,460.86 (+0.01%)
NVDA   352.84 (+0.62%)
CGC   16.91 (+1.68%)
BABA   219.25 (+0.55%)
MU   53.58 (+4.61%)
GE   8.32 (+7.36%)
TSLA   870.87 (+0.75%)
AMD   52.41 (-0.42%)
T   32.67 (+2.74%)
F   7.23 (+10.05%)
GILD   77.00 (-0.70%)
DIS   126.33 (+2.13%)
BAC   28.43 (+6.16%)
BA   207.14 (+12.39%)
AAPL   327.75 (+1.68%)
MSFT   184.81 (+1.03%)
FB   230.09 (+1.68%)
GOOGL   1,433.00 (+1.32%)
AMZN   2,460.86 (+0.01%)
NVDA   352.84 (+0.62%)
CGC   16.91 (+1.68%)
BABA   219.25 (+0.55%)
MU   53.58 (+4.61%)
GE   8.32 (+7.36%)
TSLA   870.87 (+0.75%)
AMD   52.41 (-0.42%)
T   32.67 (+2.74%)
F   7.23 (+10.05%)
GILD   77.00 (-0.70%)
DIS   126.33 (+2.13%)
BAC   28.43 (+6.16%)
BA   207.14 (+12.39%)
AAPL   327.75 (+1.68%)
MSFT   184.81 (+1.03%)
FB   230.09 (+1.68%)
GOOGL   1,433.00 (+1.32%)
AMZN   2,460.86 (+0.01%)
NVDA   352.84 (+0.62%)
CGC   16.91 (+1.68%)
BABA   219.25 (+0.55%)
MU   53.58 (+4.61%)
GE   8.32 (+7.36%)
TSLA   870.87 (+0.75%)
AMD   52.41 (-0.42%)
T   32.67 (+2.74%)
F   7.23 (+10.05%)
GILD   77.00 (-0.70%)
DIS   126.33 (+2.13%)
BAC   28.43 (+6.16%)
BA   207.14 (+12.39%)
Log in

NASDAQ:BIOLBIOLASE Stock Price, Forecast & News

$0.74
+0.22 (+42.31 %)
(As of 06/5/2020 11:02 AM ET)
Add
Compare
Today's Range
$0.47
Now: $0.74
$0.78
50-Day Range
$0.38
MA: $0.43
$0.54
52-Week Range
$0.21
Now: $0.74
$2.07
Volume253,671 shs
Average Volume2.30 million shs
Market Capitalization$23.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment comprising three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products include 3Shape TRIOS intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Read More
BIOLASE logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.80 million
Book Value$0.01 per share

Profitability

Net Income$-17,850,000.00

Miscellaneous

Employees190
Market Cap$23.49 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

How has BIOLASE's stock been impacted by COVID-19 (Coronavirus)?

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIOL shares have decreased by 0.2% and is now trading at $0.5790. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BIOLASE?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIOLASE.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BIOLASE.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) issued its quarterly earnings data on Thursday, May, 7th. The medical technology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.05. The medical technology company earned $4.78 million during the quarter. BIOLASE had a negative return on equity of 645.85% and a negative net margin of 58.75%. View BIOLASE's earnings history.

When did BIOLASE's stock split? How did BIOLASE's stock split work?

Shares of BIOLASE reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for BIOL?

2 brokerages have issued 12 month price objectives for BIOLASE's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate BIOLASE's share price to reach $2.50 in the next year. This suggests a possible upside of 331.8% from the stock's current price. View analysts' price targets for BIOLASE.

Has BIOLASE been receiving favorable news coverage?

News headlines about BIOL stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIOLASE earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned media headlines about the medical technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutBIOLASE.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (4.37%). Company insiders that own BIOLASE stock include Garrett Sato, Jack W Schuler, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View institutional ownership trends for BIOLASE.

Which major investors are buying BIOLASE stock?

BIOL stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg, and Todd Norbe. View insider buying and selling activity for BIOLASE.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.58.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $18.38 million and generates $37.80 million in revenue each year. The medical technology company earns $-17,850,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. BIOLASE employs 190 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is www.biolase.com.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.